{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:42:56Z","timestamp":1788554576465,"version":"build-2803163510"},"reference-count":195,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>During the last decade, the underlying pathogenic mechanisms of acute myeloid leukemia (AML) have been the subject of extensive study which has considerably increased our understanding of the disease. However, both resistance to chemotherapy and disease relapse remain the principal obstacles to successful treatment. Because of acute and chronic undesirable effects frequently associated with conventional cytotoxic chemotherapy, consolidation chemotherapy is not feasible, especially for elderly patients, which has attracted a growing body of research to attempt to tackle this problem. Immunotherapies for acute myeloid leukemia, including immune checkpoint inhibitors, monoclonal antibodies, dendritic cell (DC) vaccines, together with T-cell therapy based on engineered antigen receptor have been developed recently. Our review presents the recent progress in immunotherapy for the treatment of AML and discusses effective therapies that have the most potential and major challenges.<\/jats:p>","DOI":"10.3389\/fphar.2023.1151032","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T04:59:28Z","timestamp":1681880368000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges"],"prefix":"10.3389","volume":"14","author":[{"given":"Ying","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"6071","DOI":"10.1038\/s41467-021-26282-z","article-title":"Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy","volume":"12","author":"Abbas","year":"2021","journal-title":"Nat. Commun."},{"key":"B2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/bmt.2016.274","article-title":"PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation","volume":"52","author":"Albring","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"B3","volume-title":"Third patient death reported in SL-401 drug trial for patients with BPDCN and AML","year":"2016"},{"key":"B4","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1124\/pr.114.009456","article-title":"Dendritic cells as pharmacological tools for cancer immunotherapy","volume":"67","author":"Anguille","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood-2017-04-780155","article-title":"Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia","volume":"130","author":"Anguille","year":"2017","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/nejmoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.ymthe.2017.04.017","article-title":"Balance of anti-cd123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia","volume":"25","author":"Arcangeli","year":"2017","journal-title":"Mol. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: Extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1182\/blood.2020010477","article-title":"Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody","volume":"138","author":"Augsberger","year":"2021","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2165\/11584530-000000000-00000","article-title":"Tremelimumab","volume":"10","year":"2010","journal-title":"Drugs R&D"},{"key":"B11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11912-020-00919-6","article-title":"Diagnostic and therapeutic considerations for extramedullary leukemia","volume":"22","author":"Bakst","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/gt.2010.174","article-title":"Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells","volume":"18","author":"Barber","year":"2011","journal-title":"Gene Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/17512433.2018.1478725","article-title":"Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia","volume":"11","author":"Baron","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/2326-6066.cir-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1182\/blood.v90.3.1217.1217_1217_1225","article-title":"High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome","volume":"90","author":"Bergmann","year":"1997","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s00262-010-0909-y","article-title":"In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors","volume":"59","author":"Berthon","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1945803","DOI":"10.1080\/2162402X.2021.1945803","article-title":"Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment","volume":"10","author":"Bonnevaux","year":"2021","journal-title":"Oncoimmunology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1930391","DOI":"10.1080\/2162402X.2021.1930391","article-title":"Increased frequency of TIGIT(+)CD73-CD8(+) T cells with a TOX(+) TCF-1low profile in patients with newly diagnosed and relapsed AML","volume":"10","author":"Brauneck","year":"2021","journal-title":"Oncoimmunology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/ajh.24014","article-title":"WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides","volume":"90","author":"Brayer","year":"2015","journal-title":"Am. J. Hematol."},{"key":"B20","first-page":"1490","article-title":"Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.stem.2014.11.010","article-title":"Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy","volume":"15","author":"Bruedigam","year":"2014","journal-title":"Cell stem Cell"},{"key":"B22","volume-title":"Phase III CASCADE trial of vadastuximab talirine in front-line AML discontinued","year":"2017"},{"key":"B23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-020-00853-x","article-title":"Expression patterns of immune checkpoints in acute myeloid leukemia","volume":"13","author":"Chen","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"622","DOI":"10.4161\/cbt.7.5.5689","article-title":"Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia","volume":"7","author":"Chen","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1111\/ajco.13236","article-title":"Higher frequency of the CTLA-4(+) LAG-3(+) T-cell subset in patients with newly diagnosed acute myeloid leukemia","volume":"16","author":"Chen","year":"2020","journal-title":"Asia-Pacific J. Clin. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1080\/21645515.2021.1943991","article-title":"A phase I\/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients","volume":"17","author":"Chevallier","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/nrclinonc.2015.210","article-title":"Molecular therapy for acute myeloid leukaemia","volume":"13","author":"Coombs","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B32","first-page":"598","article-title":"Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML","volume-title":"Blood","author":"Cortes","year":"2018"},{"key":"B33","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13045-020-00975-2","article-title":"Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia","volume":"13","author":"Cortes","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1182\/blood.v85.9.2315.bloodjournal8592315","article-title":"Telomerase activity in normal leukocytes and in hematologic malignancies","volume":"85","author":"Counter","year":"1995","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1080\/10428194.2017.1361023","article-title":"Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia","volume":"59","author":"Cruz","year":"2018","journal-title":"Leukemia lymphoma"},{"key":"B36","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","article-title":"Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 (c259)T cells in synovial sarcoma","volume":"8","author":"D'Angelo","year":"2018","journal-title":"Cancer Discov."},{"key":"B37","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: A nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2018","journal-title":"Cancer Discov."},{"key":"B38","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: A nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov."},{"key":"B39","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: A comprehensive review and 2016 update","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood cancer J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","article-title":"LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration","volume":"562","author":"Deng","year":"2018","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1182\/blood-2007-07-101311","article-title":"NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities","volume":"111","author":"Diermayr","year":"2008","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.3389\/fimmu.2020.01710","article-title":"PD-L1 is expressed and promotes the expansion of regulatory T cells in acute myeloid leukemia","volume":"11","author":"Dong","year":"2020","journal-title":"Front. Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"23301","DOI":"10.1038\/s41598-021-02767-1","article-title":"TERT genetic variability and telomere length as factors affecting survival and risk in acute myeloid leukaemia","volume":"11","author":"Dratwa","year":"2021","journal-title":"Sci. Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J."},{"key":"B48","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1038\/s41467-021-26683-0","article-title":"Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia","volume":"12","author":"El Khawanky","year":"2021","journal-title":"Nat. Commun."},{"key":"B49","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1182\/blood.v128.22.211.211","article-title":"A phase 1b study of vadastuximab talirine in combination with 7+3 induction therapy for patients with newly diagnosed acute myeloid leukemia (AML)","volume":"128","author":"Erba","year":"2016","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nature25187","article-title":"High response rate to PD-1 blockade in desmoplastic melanomas","volume":"553","author":"Eroglu","year":"2018","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1182\/blood-2018-03-841171","article-title":"A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML","volume":"132","author":"Fathi","year":"2018","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1200\/jco.2005.09.133","article-title":"Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia","volume":"23","author":"Feldman","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B53","first-page":"3973","article-title":"Clonal expansion of bone marrow CD8(+) T cells in acute myeloid leukemia patients at new diagnosis and after chemotherapy","volume":"10","author":"Feng","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/nm.4410","article-title":"Clonal evolution in leukemia","volume":"23","author":"Ferrando","year":"2017","journal-title":"Nat. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/s0140-6736(12)61727-9","article-title":"Acute myeloid leukaemia in adults","volume":"381","author":"Ferrara","year":"2013","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/sj.leu.2404720","article-title":"CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease","volume":"21","author":"Fevery","year":"2007","journal-title":"Leukemia"},{"key":"B57","first-page":"2638","article-title":"A phase 2 study of actinium-225-lintuzumab in older patients with previously untreated acute myeloid leukemia (AML) unfit for intensive chemotherapy","volume":"130","author":"Finn Le","year":"2017","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1084\/jem.20041379","article-title":"High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens","volume":"201","author":"Germeau","year":"2005","journal-title":"J. Exp. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."},{"key":"B61","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejca.2016.12.041","article-title":"Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges","volume":"78","author":"Giroux Leprieur","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e003392","DOI":"10.1136\/jitc-2021-003392","article-title":"Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia","volume":"10","author":"Goswami","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nrc.2016.3","article-title":"Leukaemia 'firsts' in cancer research and treatment","volume":"16","author":"Greaves","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00262-020-02490-2","article-title":"Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition","volume":"69","author":"Greiner","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1158\/2326-6066.CIR-17-0117","article-title":"Novel \"elements\" of immune suppression within the tumor microenvironment","volume":"5","author":"Gurusamy","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.cell.2017.08.031","article-title":"Converting cold into hot tumors by combining immunotherapies","volume":"170","author":"Haanen","year":"2017","journal-title":"Cell"},{"key":"B69","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1080\/14712598.2020.1776255","article-title":"Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy","volume":"21","author":"Hartley","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"B70","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3109\/10428194.2014.956316","article-title":"A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia","volume":"56","author":"He","year":"2015","journal-title":"Leukemia lymphoma"},{"key":"B72","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/nejmoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/jlb.ma0119-021r","article-title":"A skewed distribution and increased PD-1+V\u03b2+CD4+\/CD8+ T cells in patients with acute myeloid leukemia","volume":"106","author":"Huang","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"B75","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1158\/1078-0432.CCR-19-2329","article-title":"FDA approval summary: Tagraxofusp-erzs for treatment of blastic plasmacytoid dendritic cell neoplasm","volume":"26","author":"Jen","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-17-3179","article-title":"FDA approval: Gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia","volume":"24","author":"Jen","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1182\/blood.2020009192","article-title":"Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia","volume":"138","author":"Jetani","year":"2021","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","article-title":"First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s40425-018-0432-9","article-title":"CD33\/CD3-bispecific T-cell engaging (BiTE\u00ae) antibody construct targets monocytic AML myeloid-derived suppressor cells","volume":"6","author":"Jitschin","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B81","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1001\/jamaoncol.2015.0617","article-title":"Toward individualized therapy in acute myeloid leukemia: A contemporary review","volume":"1","author":"Kadia","year":"2015","journal-title":"JAMA Oncol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-14-1559","article-title":"Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer","volume":"21","author":"Kageyama","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1126\/science.355.6332.1386-b","article-title":"CD28 is a critical target for PD-1 blockade","volume":"355","author":"Kelly","year":"2017","journal-title":"Science"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/leu.2016.309","article-title":"Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia","volume":"31","author":"Khan","year":"2017","journal-title":"Leukemia"},{"key":"B86","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1002\/cncr.30696","article-title":"Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia","volume":"123","author":"Khoury","year":"2017","journal-title":"Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"B88","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1007\/s00262-022-03202-8","article-title":"First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: A single-center experience","volume":"71","author":"Kreutmair","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"B89","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","article-title":"CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330","volume":"123","author":"Krupka","year":"2014","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/leu.2015.214","article-title":"Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: Reversing a T-cell-induced immune escape mechanism","volume":"30","author":"Krupka","year":"2016","journal-title":"Leukemia"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1038\/s41375-019-0645-z","article-title":"Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents","volume":"34","author":"Kubasch","year":"2020","journal-title":"Leukemia"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1182\/blood-2013-03-491506","article-title":"SGN-CD33A: A novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML","volume":"122","author":"Kung Sutherland","year":"2013","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/jof7030186","article-title":"Invasive fungal diseases in children with hematological malignancies treated with therapies that target cell surface antigens: Monoclonal antibodies, immune checkpoint inhibitors and CAR T-cell therapies","volume":"7","author":"Kyriakidis","year":"2021","journal-title":"J. Fungi (Basel)"},{"key":"B94","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: Final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"B95","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1200\/JCO.21.01595","article-title":"CD123 expression is associated with high-risk disease characteristics in childhood acute myeloid leukemia: A report from the children's oncology group","volume":"40","author":"Lamble","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"14331","DOI":"10.1073\/pnas.1916206117","article-title":"Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia","volume":"117","author":"Lamble","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B97","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/blood.v128.22.215.215","article-title":"Results from ongoing phase 2 trial of SL-401 as consolidation therapy in patients with acute myeloid leukemia (AML) in remission with high relapse risk including minimal residual disease (MRD)","volume":"128","author":"Lane","year":"2016","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1038\/bcj.2015.68","article-title":"T-cell ligands modulate the cytolytic activity of the CD33\/CD3 BiTE antibody construct, AMG 330","volume":"5","author":"Laszlo","year":"2015","journal-title":"Blood Cancer J."},{"key":"B99","doi-asserted-by":"publisher","first-page":"43281","DOI":"10.18632\/oncotarget.9674","article-title":"Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia","volume":"7","author":"Laszlo","year":"2016","journal-title":"Oncotarget"},{"key":"B100","doi-asserted-by":"publisher","first-page":"LBA100","DOI":"10.1200\/jco.2015.33.18_suppl.lba100","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","article-title":"Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia","volume":"40","author":"Leick","year":"2022","journal-title":"Cancer Cell"},{"key":"B102","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/jco.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/14712598.2018.1425389","article-title":"Rituximab in the management of acute lymphoblastic leukemia","volume":"18","author":"Levato","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"B104","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cell.2015.05.047","article-title":"Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis","volume":"162","author":"Levine","year":"2015","journal-title":"Cell"},{"key":"B105","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-022-01541-9","article-title":"A novel approach for relapsed\/refractory FLT3(mut+) acute myeloid leukaemia: Synergistic effect of the combination of bispecific FLT3scFv\/nkg2d-CAR T cells and gilteritinib","volume":"21","author":"Li","year":"2022","journal-title":"Mol. Cancer"},{"key":"B106","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3389\/fphar.2019.00609","article-title":"A review of efficacy and safety of checkpoint inhibitor for the treatment of acute myeloid leukemia","volume":"10","author":"Liao","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3892\/mmr.2021.11847","article-title":"Cytotoxic effect of CLL-1 CAR-T cell immunotherapy with PD-1 silencing on relapsed\/refractory acute myeloid leukemia","volume":"23","author":"Lin","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"B108","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: A multicenter study of kte-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol. Ther."},{"key":"B109","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.omto.2020.04.009","article-title":"Rapidly switchable universal CAR-T cells for treatment of cd123-positive leukemia","volume":"17","author":"Loff","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"B110","first-page":"615","article-title":"Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment","volume":"12","author":"Ma","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"B111","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/978-3-319-53156-4_4","article-title":"Harnessing the immune system against leukemia: Monoclonal antibodies and checkpoint strategies for AML","volume":"995","author":"Masarova","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.clml.2018.02.017","article-title":"A phase I\/II trial of the combination of azacitidine and gemtuzumab ozogamicin for treatment of relapsed acute myeloid leukemia","volume":"18","author":"Medeiros","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"key":"B114","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","article-title":"Therapeutic vaccines for cancer: An overview of clinical trials","volume":"11","author":"Melero","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrclinonc.2016.144","article-title":"Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape","volume":"14","author":"Mohme","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41375-020-0773-5","article-title":"Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: Results from a multicenter, randomized, phase 2\/3 study","volume":"35","author":"Montesinos","year":"2021","journal-title":"Leukemia"},{"key":"B117","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1182\/blood-2013-01-480129","article-title":"Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment","volume":"122","author":"Mussai","year":"2013","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/bjh.15818","article-title":"Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell\/AML vaccine","volume":"185","author":"Nahas","year":"2019","journal-title":"Br. J. Haematol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood.v128.22.763.763","article-title":"Phase IB\/II study of nivolumab in combination with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML)","volume":"128","author":"Naval Daver","year":"2016","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/nrclinonc.2017.88","article-title":"Monitoring immune-checkpoint blockade: Response evaluation and biomarker development","volume":"14","author":"Nishino","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3324\/haematol.2014.112748","article-title":"Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia","volume":"100","author":"O'Hear","year":"2015","journal-title":"Haematologica"},{"key":"B122","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/1744-9987.13828","article-title":"Wilms' tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia","volume":"26","author":"Ogasawara","year":"2022","journal-title":"Ther. Apher. Dial."},{"key":"B123","first-page":"619","article-title":"Clinical implications of telomerase activity levels in acute leukemia","volume":"3","author":"Ohyashiki","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"B124","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/cncr.32796","article-title":"Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML\/MDS who are treated with checkpoint inhibitors","volume":"126","author":"Oran","year":"2020","journal-title":"Cancer"},{"key":"B125","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","article-title":"Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion","volume":"572","author":"Paczulla","year":"2019","journal-title":"Nature"},{"key":"B126","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1200\/JCO.22.00034","article-title":"Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm","volume":"40","author":"Pemmaraju","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1182\/blood.2021010867","article-title":"Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation","volume":"137","author":"Penter","year":"2021","journal-title":"Blood"},{"key":"B128","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"key":"B129","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1182\/blood-2011-12-398370","article-title":"Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML","volume":"119","author":"Pollard","year":"2012","journal-title":"Blood"},{"key":"B131","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3109\/02688697.2014.994473","article-title":"Active dendritic cell immunotherapy for glioblastoma: Current status and challenges","volume":"29","author":"Polyzoidis","year":"2015","journal-title":"Br. J. Neurosurg."},{"key":"B132","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1182\/blood.2021013733","article-title":"Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL","volume":"139","author":"Qi","year":"2022","journal-title":"Blood"},{"key":"B133","doi-asserted-by":"publisher","first-page":"e003149","DOI":"10.1136\/jitc-2021-003149","article-title":"Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design","volume":"9","author":"Qin","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B134","doi-asserted-by":"publisher","first-page":"e480","DOI":"10.1016\/S2352-3026(19)30114-0","article-title":"Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: A single-arm, phase 2 study","volume":"6","author":"Ravandi","year":"2019","journal-title":"Lancet. Haematol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1158\/1078-0432.CCR-16-0350","article-title":"Characterization of CD33\/CD3 tetravalent bispecific tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia","volume":"22","author":"Reusch","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B136","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/mt.2013.154","article-title":"Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia","volume":"21","author":"Ritchie","year":"2013","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B137","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"B138","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"B140","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1182\/blood.v112.11.2956.2956","article-title":"A phase 1 and correlative biological study of CSL360 (anti-CD123 mAb) in AML","volume":"112","author":"Roberts","year":"2008","journal-title":"Blood"},{"key":"B141","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1200\/JCO.2013.52.8562","article-title":"International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed\/refractory acute myeloid leukemia","volume":"32","author":"Roboz","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1158\/1078-0432.CCR-21-3712","article-title":"Treatment of patients with acute myeloid leukemia with the targeted alpha-particle nanogenerator actinium-225-lintuzumab","volume":"28","author":"Rosenblat","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"B143","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.1158\/1078-0432.CCR-10-0382","article-title":"Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia","volume":"16","author":"Rosenblat","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"B144","doi-asserted-by":"publisher","first-page":"368ra171","DOI":"10.1126\/scitranslmed.aag1298","article-title":"Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions","volume":"8","author":"Rosenblatt","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"B145","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B146","doi-asserted-by":"publisher","first-page":"eabg8027","DOI":"10.1126\/scitranslmed.abg8027","article-title":"CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function","volume":"14","author":"Ruggiero","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"B147","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.3324\/haematol.2017.186742","article-title":"NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed\/refractory acute myeloid leukemia patient","volume":"103","author":"Sallman","year":"2018","journal-title":"Haematologica"},{"key":"B148","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/blood.2020006158","article-title":"TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype","volume":"136","author":"Sallman","year":"2020","journal-title":"Blood"},{"key":"B149","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"B150","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1002\/cncr.33690","article-title":"A phase 1b\/2 study of azacitidine with PD-L1 antibody avelumab in relapsed\/refractory acute myeloid leukemia","volume":"127","author":"Saxena","year":"2021","journal-title":"Cancer"},{"key":"B151","doi-asserted-by":"publisher","first-page":"e147598","DOI":"10.1172\/JCI147598","article-title":"Somatic reversion impacts myelodysplastic syndromes and acute myeloid leukemia evolution in the short telomere disorders","volume":"131","author":"Schratz","year":"2021","journal-title":"J. Clin. Investigation"},{"key":"B152","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1158\/1078-0432.CCR-15-2205","article-title":"Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells","volume":"22","author":"Schreibelt","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B153","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/nrg3980","article-title":"Single-cell epigenomics: Techniques and emerging applications","volume":"16","author":"Schwartzman","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"B154","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/s0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"B155","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.clml.2021.10.012","article-title":"Infectious complications among patients with AML treated with immune checkpoint inhibitors","volume":"22","author":"Spallone","year":"2022","journal-title":"Clin. lymphoma, myeloma and leukemia"},{"key":"B156","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1182\/blood-2017-06-789800","article-title":"A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"B157","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nature06175","article-title":"Taking dendritic cells into medicine","volume":"449","author":"Steinman","year":"2007","journal-title":"Nature"},{"key":"B158","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1006\/scbi.2000.0339","article-title":"Telomerase and human tumorigenesis","volume":"10","author":"Stewart","year":"2000","journal-title":"Seminars Cancer Biol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.3324\/haematol.2020.259457","article-title":"Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model","volume":"106","author":"Stroopinsky","year":"2021","journal-title":"Haematologica"},{"key":"B160","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1038\/s41467-022-29668-9","article-title":"Allogeneic TCR\u03b1\u03b2 deficient CAR T-cells targeting CD123 in acute myeloid leukemia","volume":"13","author":"Sugita","year":"2022","journal-title":"Nat. Commun."},{"key":"B161","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13045-021-01163-6","article-title":"SIRP\u03b1-\u03b1CD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells","volume":"14","author":"Tahk","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"B163","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40364-020-0185-8","article-title":"Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML","volume":"8","author":"Tan","year":"2020","journal-title":"Biomark. Res."},{"key":"B164","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/annonc\/mdx755","article-title":"Comprehensive analysis of the clinical immuno-oncology landscape","volume":"29","author":"Tang","year":"2017","journal-title":"Ann. Oncol."},{"key":"B165","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1158\/1078-0432.CCR-19-3003","article-title":"Characterization of immune dysfunction and identification of prognostic immune-related risk factors in acute myeloid leukemia","volume":"26","author":"Tang","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B166","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/2040620718774268","article-title":"Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: How far up the road have we traveled?","volume":"9","author":"Tasian","year":"2018","journal-title":"Ther. Adv. Hematol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1182\/blood-2005-03-1072","article-title":"Hematopoietic stem cells express multiple myeloid markers: Implications for the origin and targeted therapy of acute myeloid leukemia","volume":"106","author":"Taussig","year":"2005","journal-title":"Blood"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1182\/blood-2017-06-791202","article-title":"Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS","volume":"130","author":"Tawara","year":"2017","journal-title":"Blood"},{"key":"B169","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B170","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1172\/jci129204","article-title":"Immune escape and immunotherapy of acute myeloid leukemia","volume":"130","author":"Vago","year":"2020","journal-title":"J. Clin. Investigation"},{"key":"B171","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.3389\/fimmu.2020.01804","article-title":"HA-1H T-cell receptor gene transfer to redirect virus-specific T cells for treatment of hematological malignancies after allogeneic stem cell transplantation: A phase 1 clinical study","volume":"11","author":"van Balen","year":"2020","journal-title":"Front. Immunol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00262-018-2198-9","article-title":"A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia","volume":"67","author":"van de Loosdrecht","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"B173","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1038\/s41409-020-0966-6","article-title":"PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity","volume":"55","author":"van Ens","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"B174","doi-asserted-by":"publisher","first-page":"13824","DOI":"10.1073\/pnas.1008051107","article-title":"Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination","volume":"107","author":"Van Tendeloo","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B175","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1200\/JCO.20.02224","article-title":"T-cell therapy for lymphoma using nonengineered multiantigen-targeted T cells is safe and produces durable clinical effects","volume":"39","author":"Vasileiou","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B176","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"key":"B177","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1182\/blood.2020006921","article-title":"CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy","volume":"137","author":"Willier","year":"2021","journal-title":"Blood"},{"key":"B178","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.cell.2015.07.045","article-title":"PD-1 blockers","volume":"162","author":"Wolchok","year":"2015","journal-title":"Cell"},{"key":"B179","doi-asserted-by":"publisher","first-page":"e567","DOI":"10.1038\/bcj.2017.52","article-title":"CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission","volume":"7","author":"Xie","year":"2017","journal-title":"Blood Cancer J."},{"key":"B180","doi-asserted-by":"publisher","first-page":"686156","DOI":"10.3389\/fonc.2021.686156","article-title":"PD-1 and TIGIT are highly Co-expressed on CD8(+) T cells in AML patient bone marrow","volume":"11","author":"Xu","year":"2021","journal-title":"Front. Oncol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"38584","DOI":"10.1021\/acsami.2c11538","article-title":"CD123 antagonistic peptides assembled with nanomicelles act as monotherapeutics to combat refractory acute myeloid leukemia","volume":"14","author":"Xu","year":"2022","journal-title":"ACS Appl. Mater. interfaces"},{"key":"B182","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s13045-021-01206-y","article-title":"A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia","volume":"14","author":"Xu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"B184","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-022-00694-6","article-title":"Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: First-in-human clinical study","volume":"12","author":"Yang","year":"2022","journal-title":"Blood cancer J."},{"key":"B185","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-017-0543-7","article-title":"Precision therapy for acute myeloid leukemia","volume":"11","author":"Yang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"639217","DOI":"10.3389\/fimmu.2021.639217","article-title":"Case report: Combination therapy with PD-1 blockade for acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation resulted in fatal GVHD","volume":"12","author":"Yao","year":"2021","journal-title":"Front. Immunol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B188","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1182\/blood.2021012519","article-title":"Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation","volume":"139","author":"You","year":"2022","journal-title":"Blood"},{"key":"B189","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet. Oncol."},{"key":"B190","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1158\/2643-3230.BCD-21-0070","article-title":"Phase II trial of pembrolizumab after high-dose cytarabine in relapsed\/refractory acute myeloid leukemia","volume":"2","author":"Zeidner","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"B191","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1182\/blood-2009-03-206672","article-title":"PD-1\/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model","volume":"114","author":"Zhang","year":"2009","journal-title":"Blood"},{"key":"B192","first-page":"799","article-title":"Telomerase activity in human acute myelogenous leukemia: Inhibition of telomerase activity by differentiation-inducing agents","volume":"2","author":"Zhang","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"B193","doi-asserted-by":"publisher","first-page":"E46","DOI":"10.1002\/ajh.26043","article-title":"A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia","volume":"96","author":"Zheng","year":"2021","journal-title":"Am. J. Hematol."},{"key":"B194","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1182\/blood-2009-03-208181","article-title":"Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia","volume":"114","author":"Zhou","year":"2009","journal-title":"Blood"},{"key":"B195","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1151032\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T04:59:36Z","timestamp":1681880376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1151032\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":195,"alternative-id":["10.3389\/fphar.2023.1151032"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1151032","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"article-number":"1151032"}}